Skip to content
Bomb Report – Lifestyle
Author:
Transpire Bio
Transpire Bio to Present at the 2026 BIO International Convention
June 18, 2026
Transpire Bio’s ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
May 11, 2026
Transpire Bio Announces Opening of New Satellite R&D Facility in Shanghai, China
April 28, 2026
Transpire Bio Strengthens its Leadership Team with Appointment of Ewan Livesey as Head of Business Development
March 17, 2026
Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
March 5, 2026